New York, New York–(Newsfile Corp. – January 5, 2025) – Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU) and certain of its officers.
Definition of category
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or acquired Caribou securities between July 14, 2023 and July 16, 2024, including both dates (the “Class Period”). ). ). These investors are encouraged to join this cause by visiting the company's website: bgandg.com/CRBU.
Case details
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and future prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) overstated the safety, efficacy, and durability of CB-010 compared to autologous CAR-T cell therapies approved in the treatment of patients with of r/r B-NHL and/or LBCL, as well as the overall clinical results and commercial prospects of CB-010; (2) Caribou was exposed to a significant risk that it would not have sufficient cash, liquidity and/or other capital to fund its current business operations, including preclinical research activities associated with its allogeneic CAR-NK platform; (3) all of the foregoing would likely have a material adverse effect on Caribou's business and operations; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.
What's next?
A class action lawsuit has already been filed. If you would like to review a copy of the complaint, you can visit the company's website: bgandg.com/CRBU. Or you can contact Peritz Bronstein, Esq. Or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffer a loss in Caribou, you have until February 24, 2025 to ask the court to appoint you as lead plaintiff. Your ability to participate in any recovery does not require that you serve as lead plaintiff.
There is no cost to you
We represent investors in class actions on a contingency fee basis. This means that we will ask the court to reimburse us for out-of-pocket expenses and attorney fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Goertz and Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud and shareholder derivative litigation. Our firm has recovered hundreds of millions of dollars for investors nationwide.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235262
